Experimental Hematology
Volume 37, Issue 9 , Pages 1030-1037 , September 2009

Comparative analyses of the small molecule thrombopoietin receptor agonist eltrombopag and thrombopoietin on in vitro platelet function

  • Joseph A. Erhardt

      Affiliations

    • Department of Oncology, GlaxoSmithKline, Collegeville, Pa., USA
    • Corresponding Author InformationOffprint requests to: Joseph Erhardt, Ph.D., Department of Oncology, GlaxoSmithKline, 1250 South Collegeville Road, Collegeville, PA 19426
    • ,
  • Connie L. Erickson-Miller

      Affiliations

    • Department of Oncology, GlaxoSmithKline, Collegeville, Pa., USA
    • ,
  • Manuel Aivado

      Affiliations

    • Department of Oncology, GlaxoSmithKline, Collegeville, Pa., USA
    • ,
  • Melanie Abboud

      Affiliations

    • Department of Vascular Biology, GlaxoSmithKline, Collegeville, Pa., USA
    • ,
  • Kodandaram Pillarisetti

      Affiliations

    • Department of Vascular Biology, GlaxoSmithKline, Collegeville, Pa., USA
    • ,
  • John R. Toomey

      Affiliations

    • Department of Vascular Biology, GlaxoSmithKline, Collegeville, Pa., USA

Received 10 June 2009 ,Revised 22 June 2009 ,Accepted 24 June 2009.

References 

  1. Wendling F. Thrombopoietin: its role from early hematopoiesis to platelet production. Haematologica. 1999;84:158–166
  2. Geddis AE, Linden HM, Kaushansky K. Thrombopoietin: a pan-hematopoietic cytokine. Cytokine Growth Factor Rev. 2002;13:61–73
  3. Kaushansky K, Drachman JG. The molecular and cellular biology of thrombopoietin: the primary regulator of platelet production. Oncogene. 2002;21:3359–3367
  4. Italiano JE, Shivdasani RA. Megakaryocytes and beyond: the birth of platelets. J Thromb Hameost. 2003;1:1174–1182
  5. Demetri GD. Targeted approaches for the treatment of thrombocytopenia. Oncologist. 2001;6(Suppl 5):15–23
  6. Kuter DJ. New thrombopoietic growth factors. Blood. 2007;109:4607–4616
  7. Debili N, Wendling F, Cosman D, et al. The Mpl receptor is expressed in the megakaryocytic lineage from late progenitors to platelets. Blood. 1995;85:391–401
  8. Chen J, Herceg-Harjacek L, Groopman JE, Grabarek J. Regulation of platelet activation in vitro by the c-Mpl ligand, thrombopoietin. Blood. 1995;86:4054–4062
  9. Majka M, Ratajczak J, Villaire G, et al. Thrombopoietin, but not cytokines binding to gp130 protein-coupled receptors, activates MAPKp42/44, AKT, and STAT proteins in normal human CD34+ cells, megakaryocytes, and platelets. Exp Hematol. 2002;30:751–760
  10. Kojima H, Hamazaki Y, Nagata Y, Todokoro K, Nagasawa T, Abe T. Modulation of platelet activation in vitro by thrombopoietin. Thromb Haemostat. 1995;74:1541–1545
  11. Schulze H, Ballmaier M, Welte K, Germeshausen M. Thrombopoietin induces the generation of distinct Stat1, Stat3, Stata5a and Stat5b homo- and heterodimeric complexes with different kinetics in human platelets. Exp Hematol. 2000;28:294–304
  12. Rodríguez-Liñares B, Watson SP. Thrombopoietin potentiates activation of human platelets in association with Jak2 and Tyk2 phosphorylation. Biochem J. 1996;316:93–98
  13. Ezumi Y, Takayama H, Okuma M. Thrombopoietin, c-Mpl ligand, induces tyrosine phosphorylation of Tyk2, JAK2, and STAT3, and enhances agonist-induced aggregation of platelets in vitro. FEBS Lett. 1995;374:48–52
  14. Oda A, Miyakawa Y, Druker BJ, et al. Thrombopoietin primes human platelet aggregation induced by shear stress and by multiple agonists. Blood. 1996;87:4664–4670
  15. Wun T, Paglieroni T, Hammond WP, Kaushansky K, Foster DC. Thrombopoietin is synergistic with other hematopoietic growth factors and physiologic platelet agonists for platelet activation in vitro. Am J Hematol. 1997;54:225–232
  16. Tibbles HE, Navara CS, Hupke MA, Vassilev AO, Uckun FM. Thrombopoietin induces P-selectin expression on platelets and subsequent platelet/leukocyte interactions. Biochem Biophys Res Commun. 2002;292:987–991
  17. van Os E, Wu Y, Pouwels JG, et al. Thrombopoietin increases platelet adhesion under flow and decreases rolling. Br J Haematol. 2003;121:482–490
  18. Jenkins JM, Williams D, Deng Y, et al. Phase I clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist. Blood. 2007;109:4739–4741
  19. Bussel J, Cheng G, Saleh MN, et al. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med. 2007;357:2237–2247
  20. Bussel J, Provan D, Shamsi T, et al. Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomized, double-blind, placebo-controlled trial. Lancet. 2009;373:641–648
  21. McHutchison JG, Dusheiko G, Shiffman ML, et al. Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C. N Engl J Med. 2007;357:2227–2236
  22. Erickson-Miller C, Delorme E, Tian SS, et al. Preclinical activity of eltrombopag (SB-497115), an oral, non-peptide thrombopoietic growth factor. Stem Cells. 2009;27:424–430
  23. Bell DN, Spain S, Goldsmith HL. Extracellular-free Ca++ accounts for the sex difference in the aggregation of human platelets in citrated platelet-rich plasma. Thromb Res. 1990;58:47–60
  24. Phillips DR, Teng W, Arfsten A, et al. Effect of Ca2+ on GP IIb-IIIa interactions with integrilin: enhanced GP IIb-IIIa binding and inhibition of platelet aggregation by reductions in the concentration of ionized calcium in plasma anticoagulated with citrate. Circulation. 1997;96:1488–1494
  25. Kim MJ, Park SH, Opella SJ, et al. NMR structural studies of interactions of a small, nonpeptidyl Tpo mimic with the thrombopoietin receptor extracellular juxtamembrane and transmembrane domains. J Biol Chem. 2007;282:14253–14261
  26. Nakamura T, Miyakawa Y, Miyamura A, et al. A novel nonpetidyl human c-mpl activator stimulates human megakaryocytopoiesis and thrombosis. Blood. 2006;107:4300–4307
  27. Duffy KJ, Erickson-Miller CL. The discovery of eltrombopag, an orally bioavailable TpoR agonist. In:  Metcalf BW,  Dillon S editor. Target Validation in Drug Discovery. 1st ed. Burlington, MA: Academic Press; 2007;p. 241–254
  28. Chen J, De S, Damron DS, Chen WS, Hay N, Byzova TV. Impaired platelet responses to thrombin and collagen in AKT-1-deficient mice. Blood. 2004;104:1703–1710
  29. Woulfe D, Jiang H, Morgans A, Monks R, Birnbaum M, Brass LF. Defects in secretion, aggregation, and thrombus formation in platelets from mice lacking Akt2. J Clin Invest. 2004;113:441–450
  30. Harker LA, Roskos LK, Marzec UM, et al. Effects of megakaryocyte growth and development factor on platelet production, platelet life span, and platelet function in healthy human volunteers. Blood. 2000;95:2514–2522

PII: S0301-472X(09)00258-6

doi: 10.1016/j.exphem.2009.06.011

Experimental Hematology
Volume 37, Issue 9 , Pages 1030-1037 , September 2009

Article Tools

* Image Usage & Resolution